Stock Research for GALT

GALT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GALT Stock Chart & Research Data

The GALT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GALT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GALT Due diligence Resources & Stock Charts

The GALT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GALT Detailed Price Forecast - CNN Money CNN View GALT Detailed Summary - Google Finance
Yahoo View GALT Detailed Summary - Yahoo! Finance Zacks View GALT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GALT Trends & Analysis - Trade-Ideas Barrons View GALT Major Holders - Barrons
NASDAQ View GALT Call Transcripts - NASDAQ Seeking View GALT Breaking News & Analysis - Seeking Alpha
Spotlight View GALT Annual Report - CompanySpotlight.com OTC Report View GALT OTC Short Report - OTCShortReport.com
TradeKing View GALT Fundamentals - TradeKing Charts View GALT SEC Filings - Bar Chart
WSJ View Historical Prices for GALT - The WSJ Morningstar View Performance/Total Return for GALT - Morningstar
MarketWatch View the Analyst Estimates for GALT - MarketWatch CNBC View the Earnings History for GALT - CNBC
StockMarketWatch View the GALT Earnings - StockMarketWatch MacroAxis View GALT Buy or Sell Recommendations - MacroAxis
Bullish View the GALT Bullish Patterns - American Bulls Short Pains View GALT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GALT Stock Mentions - StockTwits PennyStocks View GALT Stock Mentions - PennyStockTweets
Twitter View GALT Stock Mentions - Twitter Invest Hub View GALT Investment Forum News - Investor Hub
Yahoo View GALT Stock Mentions - Yahoo! Message Board Seeking Alpha View GALT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GALT - SECform4.com Insider Cow View Insider Transactions for GALT - Insider Cow
CNBC View GALT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GALT - OTC Markets
Yahoo View Insider Transactions for GALT - Yahoo! Finance NASDAQ View Institutional Holdings for GALT - NASDAQ


Stock Charts

FinViz View GALT Stock Insight & Charts - FinViz.com StockCharts View GALT Investment Charts - StockCharts.com
BarChart View GALT Stock Overview & Charts - BarChart Trading View View GALT User Generated Charts - Trading View




Latest Financial News for GALT


Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Posted on Tuesday March 12, 2024

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. “We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program” said Pol F


Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%
Posted on Wednesday February 21, 2024

Key Insights Galectin Therapeutics' significant retail investors ownership suggests that the key decisions are...


Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023
Posted on Monday November 13, 2023

Company Faces Higher R&D Expenses Amid Progress in Clinical Programs


UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
Posted on Monday November 13, 2023

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President


Stock Market & Investing Books

Enter a stock symbol to view the stock details.